



July 21, 2022

Scientific Innovation and Collaboration Highlighted at AIDS 2022 as Gilead Extends Leadership Efforts Toward Ending the Global HIV Epidemic

– Latest HIV Clinical Research and Development Data Drive the Next Wave of Innovation in Treatment, Prevention and Reaches Towards a Cure –

– Key Initiatives Highlight Role of Catalytic Collaboration to Help End the Epidemic for Everyone, Everywhere –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming contributions to the 24th International AIDS Conference (AIDS 2022). AIDS 2022 will be a hybrid conference, taking place in person in Montreal, Canada, as well as virtually, from July 29-August 2, 2022. As the leader in HIV innovation, the company will provide an update on its signature initiatives, key collaborations and share new scientific data from its HIV research and development programs as part of its ongoing commitment to help end the HIV epidemic for everyone, everywhere.

“Continued scientific innovation and inclusive approaches are essential in the discovery and development of person-centered options that address the evolving needs of a broad range of individuals and communities affected by HIV,” said Jared Baeten, MD, PhD, Vice President, HIV Clinical Development, Gilead Sciences. “Our scientific advancements are grounded in collaboration with community and research partners around the world. AIDS 2022 will highlight how our expertise and dedication are helping us drive the next generation of innovation in HIV treatment and prevention and reach towards cure.”

“At Gilead we recognize that scientific innovation alone will not end the epidemic, so we are committed to advancing equity, and optimizing health outcomes in partnership with the global HIV community,” said Alex Kalomparis, Senior Vice President, Public Affairs, Gilead Sciences. “The convergence of the COVID-19 pandemic and HIV epidemic has further highlighted how inequities result in adverse health outcomes. Through innovative programs like the COMPASS Initiative®, RADIANT®, and Zeroing In™, Gilead seeks to address the evolving needs of the communities most impacted by HIV.

As part of our enduring commitment to helping end the HIV epidemic, we look forward to sharing the latest from these and other key programs at AIDS 2022.”

Advancing Efforts to Address Barriers to HIV Care

At AIDS 2022, Gilead will convene a diverse, global panel – “Working Together to End the Epidemic: Guided by the Voices on the Ground” – to discuss community perspectives and Gilead’s ongoing efforts to change the future of the HIV epidemic through catalytic collaboration. The panel will discuss different challenges in delivering HIV care around the world, and programs that support practical solutions with sustainable impact toward better care for people with HIV or people who could benefit from PrEP medicines. The panel will convene on Aug. 1 at 8:00-9:00 a.m. ET.

Driving Transformational Innovation in HIV Research

Gilead is driving scientific innovation to provide solutions for the evolving needs of people affected by HIV around the world, with the goal of ending the HIV epidemic for everyone, everywhere. Gilead's long-standing research leadership and community engagement, built over decades of collaborative research and development, enable the company to help advance preclinical and clinical programs with the goal of achieving a functional cure for HIV. During AIDS 2022, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company’s continued pursuit of an HIV cure. Updates will be shared on efforts to ensure HIV clinical trials are inclusive, representative and meaningful through expanding the participation of communities most affected. Presentations from Gilead’s HIV research and development programs will include:

- Five-year cumulative outcomes from two Phase 3 trials (Study 1489 and Study 1490), evaluating Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) in treatment-naïve people living with HIV, reinforcing Biktarvy’s high barrier to resistance, durability, efficacy, and safety in people with HIV who initiated treatment with the single-tablet regimen.
- First data from the ALLIANCE trial, a first-of-its-kind study evaluating the efficacy of Biktarvy® (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) versus dolutegravir (50 mg, DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection who are initiating treatment.
- Multiple studies evaluating the antiviral activity of investigational lenacapavir, Gilead’s potential first-in-class, long-acting HIV-1 capsid inhibitor in development for the treatment and prevention of HIV-1 infection. Specifically, the studies evaluate resistance data from the CAPELLA trial in heavily treatment-experienced people with HIV, and the CALIBRATE trial in people

with HIV initiating treatment for the first time, as well as the pharmacokinetics and potential dosing schedules of lenacapavir.

- Results evaluating innovative testing methods and real-world utilization of PrEP medicines, emphasizing the company’s progress in research that can help shape the future of HIV prevention options.
- Early data identifying potential biomarkers associated with time-to-HIV-rebound (TTHR) post-antiretroviral therapy (ART) interruption following treatment with Gilead’s investigational TLR-7 agonist, vesatolimod. In a pre-clinical study, researchers tested a novel vaccine combination that showed promise in eliciting a strong anti-HIV immune response, specifically in the cell types seen in HIV-infected elite controllers. This early data suggests that this treatment regimen may have the potential to become part of a combination therapeutic approach for an HIV cure.

Summary of Presentations

Accepted abstracts at the 24th International AIDS Conference include:

HIV Treatment Research
Long-term integrated analysis of B/F/TAF in treatment-naïve adults living with HIV through five years of follow-up
Real-world HIV renal outcomes with TDF to TAF conversions
Longitudinal analysis of weight change in HIV-1 treatment-naïve and -experienced people living with HIV (PLWH) initiating/switching to an NNRTI- or INSTI-based antiretroviral therapy in four large cohort studies
Week 48 results of a phase 3 randomized controlled trial of bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF) vs dolutegravir + emtricitabine/tenofovir disoproxil fumarate (DTG+F/TDF) in ART-naïve, HIV/HBV-coinfected adults (ALLIANCE)
Investigational Long-Acting HIV Treatment Research (Lenacapavir)
Resistance analysis of long-acting lenacapavir in highly treatment-experienced people with HIV after 52 weeks of treatment
Injection site reaction experience in clinical studies of people using lenacapavir for HIV treatment
Impact of intrinsic and extrinsic factors on the pharmacokinetics of long-acting lenacapavir for treatment of HIV

Simulations for once weekly dosing of oral lenacapavir
Pharmacokinetics of a simplified subcutaneous lenacapavir regimen versus Phase 2/3 regimen
Resistance analysis of long-acting lenacapavir in treatment-naïve people with HIV at 54 weeks
HIV Prevention Research
Lipid parameters and lipid modifying agent use in participants initiating F/TAF or F/TDF for PrEP in the DISCOVER trial
Concordance between laboratory serologic testing and HIV-1 RNA testing among participants who acquired HIV in the DISCOVER trial
Real-world utilization of HIV pre-exposure prophylaxis (PrEP) by cisgender and transgender individuals in the United States
HIV Cure Research
Metabolomic and lipidomic correlates of Time-to-HIV-Rebound in viremic controllers treated with vesatolimod
FLT3 agonist enhances immunogenicity of arenavirus-vector based vaccines in macaques

For more information about Gilead at AIDS 2022, including a complete list of abstracts, please visit: <https://aids2022.org>. To learn more about Gilead’s unique collaborations around the world and the work to help end the epidemic for everyone, everywhere, visit: <https://www.gileadhivtogether.com>.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.